Two global Phase 3 trials in adults with CLL demonstrated superior efficacy for BRUKINSA in first line and relapsed/refractory settings TORONTO, ON — /CNW/ — BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235),… Read More
MISSISSAUGA, ON — Hoffmann-La Roche Limited (Roche Canada) today announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for VABYSMO® (faricimab injection), indicated for the treatment… Read More
VANCOUVER, BC — (BUSINESS WIRE) — AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, California… Read More
The Nanaimo Cancer Centre will bring the life-saving treatment closer to the people of Nanaimo, as well as residents of the central and north Island. People in Nanaimo and surrounding… Read More
Zymeworks is pleased to announce, along with their partners Jazz Pharmaceuticals and BeiGene, new and updated data from two ongoing clinical trials evaluating zanidatamab, a HER2-targeted bispecific antibody for the… Read More
